Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin
- PMID: 3153321
- DOI: 10.1007/BF00849258
Congenital nephrogenic diabetes insipidus-vasopressin and prostaglandins in response to treatment with hydrochlorothiazide and indomethacin
Abstract
In four boys with congenital nephrogenic diabetes insipidus, plasma arginine-vasopressin (AVP) and urinary excretion of prostaglandins were studied in response to treatment with hydrochlorothiazide and indomethacin. An abnormal relationship between AVP and urine osmolality was demonstrated in all patients. In the first patient, treatment with indomethacin (3 mg/kg per day) resulted in a drop of the insulin and paraminohippurate clearances. In the other three patients urinary excretion of PGE2 was raised, and fell during treatment with hydrochlorothiazide (2 mg/kg per day) and indomethacin (2 mg/kg per day). Urine flow, free water clearance and osmolar clearance decreased during treatment. A combination of both drugs is more effective than hydrochlorothiazide alone and the effect appears to be additive.
Similar articles
-
Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus.Clin Sci (Lond). 1984 Jun;66(6):709-15. doi: 10.1042/cs0660709. Clin Sci (Lond). 1984. PMID: 6723207
-
Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus.Acta Paediatr. 1994 May;83(5):522-5. doi: 10.1111/j.1651-2227.1994.tb13072.x. Acta Paediatr. 1994. PMID: 8086732
-
Comparative therapeutic benefit of indomethacin, hydrochlorothiazide, and acetyl-salicylic acid in a patient with nephrogenic diabetes insipidus.Acta Endocrinol (Copenh). 1984 Jul;106(3):311-6. doi: 10.1530/acta.0.1060311. Acta Endocrinol (Copenh). 1984. PMID: 6588700
-
Nephrogenic diabetes insipidus: clinical and pathophysiological aspects.Adv Nephrol Necker Hosp. 1984;13:247-60. Adv Nephrol Necker Hosp. 1984. PMID: 6089520 Review. No abstract available.
-
Diabetes insipidus: clinical and basic aspects.Pediatr Endocrinol Rev. 2006 Dec;4 Suppl 1:60-5. Pediatr Endocrinol Rev. 2006. PMID: 17261971 Review.
Cited by
-
Long-term growth of children with nephrogenic diabetes insipidus.Pediatr Nephrol. 2008 Nov;23(11):2007-12. doi: 10.1007/s00467-008-0844-8. Epub 2008 Jun 27. Pediatr Nephrol. 2008. PMID: 18584216
-
Nephrogenic diabetes insipidus: treat with caution.Pediatr Nephrol. 2009 Sep;24(9):1761-3. doi: 10.1007/s00467-009-1187-9. Epub 2009 Apr 17. Pediatr Nephrol. 2009. PMID: 19373493
-
Diagnosis, Treatment, and Outcomes in Children With Congenital Nephrogenic Diabetes Insipidus: A Pediatric Nephrology Research Consortium Study.Front Pediatr. 2020 Jan 21;7:550. doi: 10.3389/fped.2019.00550. eCollection 2019. Front Pediatr. 2020. PMID: 32039113 Free PMC article.
-
Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders.Pediatr Nephrol. 1987 Jul;1(3):491-7. doi: 10.1007/BF00849259. Pediatr Nephrol. 1987. PMID: 3153322
-
Prostanoids in paediatric kidney diseases.Pediatr Nephrol. 1991 Sep;5(5):639-49. doi: 10.1007/BF00856660. Pediatr Nephrol. 1991. PMID: 1911154 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous